CMMB (Chemomab Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


CMMB Chemomab Therapeutics Ltd CMMB
33 GF Score
Price $1.59
View Full Analysis

What is Chemomab Therapeutics OCF Margin %?

Chemomab Therapeutics CMMB 33 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 33/100. Among 959 Biotechnology companies, Chemomab Therapeutics ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Chemomab Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $0.00 Mil. Chemomab Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Chemomab Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Chemomab Therapeutics's current OCF Yield % is -97.21%.

The historical rank and industry rank for Chemomab Therapeutics's OCF Margin % or its related term are showing as below:


CMMB's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Chemomab Therapeutics OCF Margin % Related Terms

Chemomab Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics OCF Margin % Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CMMB
33GF Score
Chemomab Therapeutics Ltd CMMB
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Chemomab Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-11.13/0
= %

Chemomab Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Chemomab Therapeutics (CMMB) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Chemomab Therapeutics and its competitors. According to the industry distribution chart, Chemomab Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Chemomab Therapeutics' OCF Margin % too high?
Chemomab Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Chemomab Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chemomab Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' OCF Margin % compare to HCWB and MTVA?
According to the Biotechnology industry distribution chart, Chemomab Therapeutics ranks #999999 out of 959 companies for OCF Margin %. This places Chemomab Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Chemomab Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
33GF Score

Get the complete analysis for CMMB

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price